| 1 |
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al. · American Journal of Nephrology
ReviewOpen access |
2017 |
15,286 |
| 2 |
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al. · New England Journal of Medicine
Open access |
7 Mar 2012 |
7,931 |
| 3 |
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
25 Sep 2015 |
5,972 |
| 4 |
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
5,801 |
| 5 |
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine
Open access |
10 Jan 2007 |
4,813 |
| 6 |
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
21 Mar 2018 |
4,756 |
| 7 |
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al. · The Lancet
Open access |
5 Mar 2016 |
3,762 |
| 8 |
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine
|
30 May 2007 |
3,671 |
| 9 |
Comprehensive molecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al. · Nature
Open access292 authors |
23 Jun 2013 |
3,603 |
| 10 |
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
3,488 |
| 11 |
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Börje Ljungberg, Karim Bensalah, Steven E. Canfield et al. · European Urology
Open access |
21 Jan 2015 |
3,474 |
| 12 |
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Robert John Motzer, Bernard J. Escudier, Stéphane Marie. Oudard et al. · The Lancet
|
23 Jul 2008 |
3,036 |
| 13 |
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine
Open access |
9 Feb 2011 |
2,877 |
| 14 |
Renal cell carcinoma
James J.-D. Hsieh, Mark P. Purdue, Sabina Signoretti et al. · Nature Reviews Disease Primers
ReviewOpen access |
9 Mar 2017 |
2,857 |
| 15 |
A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer
James Chih‐Hsin Yang, Leah R. Haworth, Richard Mark Sherry et al. · New England Journal of Medicine
Open access |
30 Jul 2003 |
2,707 |
| 16 |
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
2,590 |
| 17 |
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida, Siân Jones, Ivana Božić et al. · Nature
Open access |
Oct 2010 |
2,563 |
| 18 |
The R.E.N.A.L. Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth
Alexander Kutikov, Robert G. Uzzo · The Journal of Urology
|
18 Jul 2009 |
2,426 |
| 19 |
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Bernard J. Escudier, Camillo Porta, Manuela Schmidinger et al. · Annals of Oncology
Open access |
Sep 2014 |
2,263 |
| 20 |
Renal-Cell Carcinoma
Robert John Motzer, Neil Harrison Bander, David M. Nanus · New England Journal of Medicine
|
19 Sep 1996 |
2,251 |
| 21 |
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard J. Escudier, Anna Pluzanska, P. Koralewski et al. · The Lancet
|
Dec 2007 |
2,234 |
| 22 |
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun Vasant Balar et al. · The Lancet
Open access |
7 Dec 2016 |
2,230 |
| 23 |
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert John Motzer, Thomas E. Hutson, Piotr Tomczak et al. · Journal of Clinical Oncology
Open access |
Jun 2009 |
2,196 |
| 24 |
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng, Wanling Xie, Meredith M. Regan et al. · Journal of Clinical Oncology
|
14 Oct 2009 |
2,159 |
| 25 |
WT-1 is required for early kidney development
Jordan A. Kreidberg, Hannu V. Sariola, Janet M. Loring et al. · Cell
|
Aug 1993 |
2,019 |
| 26 |
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
21 Aug 2013 |
1,936 |
| 27 |
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
Kornelius Schulze et al. · Nature Genetics
Open access |
30 Mar 2015 |
1,896 |
| 28 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al. · The Lancet
|
4 Nov 2011 |
1,861 |
| 29 |
Guideline for Management of the Clinical T1 Renal Mass
Steven C. Campbell, Andrew C. Novick, Arie S. Belldegrun et al. · The Journal of Urology
|
27 Aug 2009 |
1,844 |
| 30 |
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Robert John Motzer, Madhu Mazumdar, Jennifer Bacik et al. · Journal of Clinical Oncology
|
Aug 1999 |
1,812 |
| 31 |
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
13 Feb 2021 |
1,811 |
| 32 |
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
3 Mar 2021 |
1,801 |
| 33 |
Mutations of the VHL tumour suppressor gene in renal carcinoma
James R. Gnarra et al. · Nature Genetics
|
May 1994 |
1,752 |
| 34 |
Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer
Robert Charles Flanigan, Sydney E. Salmon, Brent A. Blumenstein et al. · New England Journal of Medicine
|
6 Dec 2001 |
1,742 |
| 35 |
Epidemiology of Renal Cell Carcinoma
Umberto Capitanio, Karim Bensalah, Axel Bex et al. · European Urology
Open access |
20 Sep 2018 |
1,699 |
| 36 |
Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis
Minoru Takasato, Pei Xuan Er, Han Sheng Chiu et al. · Nature
|
7 Oct 2015 |
1,661 |
| 37 |
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
Ian P. M. Tomlinson et al. · Nature Genetics
|
25 Feb 2002 |
1,650 |
| 38 |
Renal cell carcinoma
Brian I. Rini, Steven C. Campbell, Bernard J. Escudier · The Lancet
|
Mar 2009 |
1,649 |
| 39 |
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
Robert John Motzer, Marc Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology
Open access |
5 Dec 2005 |
1,637 |
| 40 |
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study
William C. W. Huang, Andrew S. Levey, Angel M. Serio et al. · The Lancet Oncology
Open access |
18 Aug 2006 |
1,618 |
| 41 |
Rising Incidence of Renal Cell Cancer in the United States
Wong Ho Chow · JAMA
|
5 May 1999 |
1,600 |
| 42 |
The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder
Jonathan I. Epstein, Mahul B. Amin, Victor R. Reuter et al. · The American Journal of Surgical Pathology
|
Dec 1998 |
1,595 |
| 43 |
Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development
Hyun Mi Kang, Seon Ho Ahn, Peter S. Choi et al. · Nature Medicine
Open access |
24 Nov 2014 |
1,580 |
| 44 |
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology
Open access |
25 Oct 2011 |
1,569 |
| 45 |
Renal-Cell Carcinoma
Herbert T. Cohen, Francis J. McGovern · New England Journal of Medicine
|
7 Dec 2005 |
1,566 |
| 46 |
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Johannes Lämmer et al. · CardioVascular and Interventional Radiology
Open access |
11 Nov 2009 |
1,563 |
| 47 |
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
Börje Ljungberg, Laurence K. Albiges, Yasmin Abu‐Ghanem et al. · European Urology
Open access |
25 Mar 2022 |
1,549 |
| 48 |
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Laura S. Schmidt et al. · Nature Genetics
|
May 1997 |
1,542 |
| 49 |
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Börje Ljungberg, Laurance Albiges, Yasmin Abu‐Ghanem et al. · European Urology
|
25 Feb 2019 |
1,529 |
| 50 |
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas B. Powles et al. · New England Journal of Medicine
Open access |
18 Sep 2020 |
1,526 |